FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials
The FDA’s Oncologic Drugs Advisory Committee on Thursday strongly supported changing clinical trials for non-small cell lung cancer drugs given in the perioperative setting, pointing out the need for a more nuanced approached to treatments before and after surgery.
FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials Read More »
